The Phase I trial is designed to assess the safety, tolerability and pharmacokinetics, as well as preliminary antitumor activity of TRC105 in patients with advanced cancer.
Charles Theuer, president and CEO of Tracon, said: “Moving an antibody into the clinic that has the potential to treat multiple solid tumors and complement anti-VEGF therapy is a major milestone for Tracon. We view TRC105 as one of the top angiogenesis inhibitors in clinical development. The target of TRC105 shares many features with the VEGF receptor. Most importantly, both are essential for angiogenesis, in that deletion of either receptor prevents blood vessel formation in utero.”